TDN 345 manufacturers
- TDN345
-
- $1670.00 / 25mg
-
2025-08-22
- CAS:134069-68-4
- Min. Order:
- Purity:
- Supply Ability: 10g
- TDN345
-
- $1670.00 / 25mg
-
2024-10-28
- CAS:134069-68-4
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | TDN 345 Basic information |
| Product Name: | TDN 345 | | Synonyms: | TDN 345;1-Oxa-3,8-diazaspiro[4.5]decan-2-one, 8-[4,4-bis(4-fluorophenyl)butyl]-3-(1,1-dimethylethyl)-4-methylene-;TDN345,TDN-345 | | CAS: | 134069-68-4 | | MF: | C28H34F2N2O2 | | MW: | 468.58 | | EINECS: | | | Product Categories: | | | Mol File: | 134069-68-4.mol |  |
| | TDN 345 Chemical Properties |
| Boiling point | 556.2±60.0 °C(Predicted) | | density | 1.18±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | pka | 9.67±0.20(Predicted) |
| | TDN 345 Usage And Synthesis |
| Uses | TDN345 is a Ca2+ antagonist, used for the treatment of vascular and senile dementia including Alzheimer's disease. | | in vivo | TDN-345 (0.1-1.0 mg/kg, p.o.) dose-dependently decreases the mortality and ischemic neurological deficit score when administered orally twice, 60 min before ischemia and 90 min after recirculation. Additionally, TDN-345 (0.2 or 1.0 mg/kg, p.o. once daily for 3 weeks after the onset of stroke) decreases the mortality and recurrence of stroke in SHRSP[2]. | | References | [1] Fukumoto H, et al. The novel compound TDN-345 induces synthesis/secretion of nerve growth factor in C6-10A glioma cells. Brain Res. 1997 Nov 7;774(1-2):87-93. DOI:10.1016/s0006-8993(97)81691-5
[2] Nakayama T, et al. Beneficial effects of TDN-345, a novel Ca2+ antagonist, on ischemic brain injury and cerebral glucose metabolism in experimental animal models with cerebrovascular lesions. Brain Res. 1997 Jul 11;762(1-2):203-10. DOI:10.1016/s0006-8993(97)00388-0 |
| | TDN 345 Preparation Products And Raw materials |
|